An observational study in Arthralgia, sponsored by University Hospital, Lille. Completed at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-05.
Sponsored by University Hospital, Lille · Observational
Self-administered questionnaire survey to determine the presence or absence of joint pain during bevacizumab treatment for lung, ovarian, colorectal cancers.
The principal end-point is the frequency of arthralgia after 6 months of treatment with Bevacizumab.
Patients treated with Bevacizumab for Lung, ovarian or colorectal cancers.
Exclusion Criteria:
patients with ovarian, colorectal or bronchopulmonary cancer receiving Bevacizumab
Frequency of arthralgia
Frequency of joint manifestations of any grade according to the CTCAE (Common Terminology Criteria for Adverse Events) scale version 4.0 observed between the start of bevacizumab treatment and 6 months of treatment.
Time frame: At 6 months
correlation between global cancer response and occurrence of arthralgia
Time frame: baseline, at 3 months, at 6 months
auto questionnaire specific to the study
16 questions concerning the location, intensity, management of joint pain
Time frame: Baseline at 3 months, at 6 months
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Lille